Kamada’s (KMDA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Kamada (NASDAQ:KMDA) in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a $11.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Kamada’s Q4 2024 earnings at $0.05 EPS, FY2025 earnings at $0.26 EPS, FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.53 EPS.

Separately, StockNews.com downgraded Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 27th.

Kamada Stock Down 0.9 %

Shares of NASDAQ:KMDA opened at $5.81 on Thursday. The firm has a market cap of $333.96 million, a P/E ratio of 20.75 and a beta of 1.05. Kamada has a 12 month low of $4.60 and a 12 month high of $6.53. The company’s 50-day moving average price is $5.48 and its two-hundred day moving average price is $5.47.

Kamada (NASDAQ:KMDA) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $42.47 million for the quarter, compared to analyst estimates of $39.70 million. Kamada had a net margin of 9.92% and a return on equity of 6.30%. As a group, equities analysts predict that Kamada will post 0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after buying an additional 100,800 shares during the last quarter. Y.D. More Investments Ltd grew its holdings in Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after acquiring an additional 690,842 shares during the period. Plato Investment Management Ltd bought a new stake in shares of Kamada during the 3rd quarter valued at $117,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Kamada in the 3rd quarter valued at $77,000. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.